FDA approves DAXXIFYTM (DaxibotulinumtoxinA-Ianm) for injection, @Revance’s first drug product approval. bit.ly/3AXmHwb #RevanceAesthetics For Full Prescribing Information including Boxed Warning and Medication Guide, see bit.ly/3QqQxPm.

Last week, #Revance celebrated the FDA approval of #DAXXIFY™ (daxibotulinumtoxinA-lanm) injection. To mark the occasion, #Revance was featured on the NASDAQ tower in Times Square in NYC! For Full Prescribing Info and Medication Guide, see bit.ly/3QqQxPm.

#Revance is pleased to announce that #OPULPlatform, the first relational commerce platform for aesthetic practices, has been selected by Octane OC as a finalist in the annual 2022 #HighTech Awards for the best innovation in the enterprise / B2B technology category

#Revance is proud to announce the publication of two peer-reviewed articles on #DAXXIFY™ (daxibotulinumtoxinA-lanm) injection for the treatment of glabellar lines in the Aesthetic Surgery Journal. For Full Prescribing Info and Medication Guide, see bit.ly/3QqQxPm

We are proud to introduce our Fall intern class of 2022! Thank you for your contribution to #Revance! #Fall2022 #Interns #SettingTheNewStandard

Join us for a company presentation by Tobin Schilke, #Revance Chief Financial Officer, at the #Stifel Healthcare Conference in New York, NY (11/15-11/16). Learn more here: investors.revance.com/news-releases/… #RevanceAesthetics #Stifel

On this day, we express our gratitude to all #Revance employees, practice partners and stakeholders. From the Revance family to yours, Happy Thanksgiving! #Thanksgiving #RevanceAesthetics

Attending the #PiperSandler Healthcare Conference in New York, NY (11/29-12/1)? Join us as #Revance Chief Executive Officer Mark J. Foley presents his industry insights and shares company developments. #RevanceAesthetics

Seasons greetings from #Revance. Warmest wishes for a healthy and happy holiday season! #HappyHolidays #RevanceAesthetics

Happy New Year! #Revance wishes you and yours a healthy and prosperous 2023. #HappyNewYear #2023 #RevanceAesthetics

Today, #Revance announced that the FDA has accepted the supplemental Biologics License Application for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia. To learn more, visit lnkd.in/dEzTVV4Z

$RVNC President, Dustin S. Sjuts, and Chief Financial Officer, Tobin Schilke are presenting at the 43rd Annual Cowen Healthcare Conference on 3/6. To learn more, click here - fal.cn/3wlYN

Revance is devastated by today’s tragic events and their aftermath at the Covenant School. Nashville is our home and we are grieving this tragedy with everyone in our community. Our thoughts and prayers are with the victims, families, and their loved ones.

$RVNC is pleased to announce that DAXXIFY® (daxibotulinumtoxinA-lanm) for injection has been approved by the Food and Drug Administration (FDA) for the treatment of cervical dystonia in adults. Read more at investors.revance.com/news-releases/….

$RVNC Investor Day is coming. Join the live broadcast from Revance Headquarters and Experience Center in Nashville, TN on Tuesday, September 19 at 8:30 AM CT: investors.revance.com/investors/Pres…

#RVNC Investor Day took place on September 19. View the presentation here: investors.revance.com/investors/even…

For the third year in a row, we made the Deloitte Technology Fast 500 list of the most innovative, fastest-growing, public and private companies. Be a part of something exciting and unique. Check out career opportunities at #Revance: bit.ly/475VWES $RVNC

Join us as #Revance Chief Financial Officer, Tobin Schilke, speaks at the Stifel Healthcare Conference. #RVNC $RVNC #SettingtheNewStandard

Today, we celebrate and honor the legacy of Dr. Martin Luther King Jr., whose words and actions echo through history and remain relevant today. “The time is always right to do what is right.” #MartinLutherKingJr #MLKday #Revance #RevanceAesthetics #RevanceTherapeutics